A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors.

被引：1
|
作者：
Infante, Jeffrey R.
Naing, Aung
Papadopoulos, Kyriakos P.
Autio, Karen A.
Ott, Patrick Alexander
Wong, Deborah Jean Lee
Falchook, Gerald Steven
Patel, Manish R.
Pant, Shubham
Whiteside, Melinda
Bendell, Johanna C.
Bauer, Todd Michael
Janku, Filip
Javle, Milind M.
Hong, David S.
Oft, Martin
机构：
[1] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] START Ctr Canc Care, San Antonio, TX USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Univ Calif Los Angeles, Los Angeles, CA USA
[7] Sarah Cannon Res Inst HealthONE, Denver, CO USA
[8] Sarah Cannon Res Inst Florida Canc Specialists, Sarasota, FL USA
[9] Univ Oklahoma, Hlth Sci Ctr, Sarah Cannon Res Inst, Oklahoma City, OK USA
[10] ARMO BioSci, Redwood City, CA USA
[11] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[12] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3017
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.
    Hollebecque, Antoine
    Soria, Jean-Charles
    Bahleda, Ratislav
    Lopez-Busto, Natividad
    Jacquet-Bescond, Anne
    Burbridge, Mike F.
    Valerie, Cattan
    Pauly, Jeanne
    Herranz, Maria
    Azaro, Analia
    Depil, Stephane
    Rodon, Jordi
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [32] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Keedy, Vicki L.
    Lenz, Heinz-Josef
    Saltz, Leonard
    Whisenant, Jennifer G.
    Berlin, Jordan D.
    Camacho, Luis H.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 860 - 868
  • [33] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Infante, Jeffrey R.
    Mendelson, David S.
    Burris, Howard A., III
    Bendell, Johanna C.
    Tolcher, Anthony W.
    Gordon, Michael S.
    Gillenwater, Heidi H.
    Arastu-Kapur, Shirin
    Wong, Hansen L.
    Papadopoulos, Kyriakos P.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 216 - 224
  • [34] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Jeffrey R. Infante
    David S. Mendelson
    Howard A. Burris
    Johanna C. Bendell
    Anthony W. Tolcher
    Michael S. Gordon
    Heidi H. Gillenwater
    Shirin Arastu-Kapur
    Hansen L. Wong
    Kyriakos P. Papadopoulos
    Investigational New Drugs, 2016, 34 : 216 - 224
  • [35] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Vicki L. Keedy
    Heinz-Josef Lenz
    Leonard Saltz
    Jennifer G. Whisenant
    Jordan D. Berlin
    Luis H. Camacho
    Investigational New Drugs, 2018, 36 : 860 - 868
  • [36] Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX)
    Hecht, J. R.
    Naing, A.
    Falchook, G.
    Patel, M. R.
    Infante, J. R.
    Aljumaily, R.
    Wong, D. J.
    Autio, K.
    Wainberg, Z. A.
    Javle, M.
    Bendell, J. C.
    Pant, S.
    Hung, A.
    Van Vlasselaer, P.
    Brown, G.
    Oft, M.
    Papadopoulos, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Wan, Qunfang
    Xiong, Wendy
    Peng, Peng
    Yang, Xiaoju
    Wu, Henry
    Ngo, Brenda
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Immunologic and objective tumor responses to PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC)
    Randolph, Hecht J.
    Aung, Naing
    Gerald, Falchook
    Manish, Patel
    Jeffrey, Infante
    Raid, Aljumaily
    Wong, Deborah
    Karen, Autio
    Zev, Wainberg
    Milind, Javle
    Johanna, Bendell
    Shubham, Pant
    Annie, Hung
    Peter, Van Vlasselaer
    Gail, Brown
    Martin, Oft
    Kyriakos, Papadopoulos
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors.
    Borazanci, Erkut Hasan
    Janku, Filip
    Hamilton, Erika P.
    Thomas, Jacob Stephen
    Sen, Shiraj
    Fu, Siqing
    Wheeler, Catherine A.
    Wages, David S.
    Matsumoto, Takeshi
    Shimoyama, Susumu
    Yamada, Naoki
    Subach, Ruth Ann
    Madden, Timothy
    Johansen, Mary
    Maier, Gary
    Cheung, Kin
    Korn, Ron
    Falchook, Gerald Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] First-in-human phase I dose-escalation study of the oral selective C-met inhibitor EMD 1204831 in patients with advanced solid tumors.
    Amin, Hesham M.
    Falchook, Gerald Steven
    Fu, Siqing
    Hong, David S.
    Tsimberidou, Apostolia Maria
    Naing, Aung
    Wheler, Jennifer J.
    Piha-Paul, Sarina Anne
    Janku, Filip
    Klevesath, Manfred B.
    Jego, Virginie
    Johne, Andreas
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345